Deals in Depth: September 2008
Executive Summary
September 2008 dealmaking highlights: Medivation landed a potential $725mm through its deal with Pfizer for AD/Huntington's candidate Dimebon. In top M&As, Japanese firm Shionogi acquired US-based Sciele for $1.4bn and Getinge paid $841mm for fellow CV-focused Datascope. Compared with September, FOPO money into biopharma almost doubled thanks to Vertex's $218mm offering, while on the device side no follow-ons were completed and private financing decreased about $100mm.
You may also be interested in...
Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans
Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.